Appendix 4C and Quarterly Activities Report - June 2025

Imagion Biosystems (ASX: IBX) has released its Appendix 4C and Quarterly Activities Report for Q2 FY2025, focusing on progress in the MagSense® HER2 breast cancer imaging program. Plans include filing an Investigational New Drug application with the FDA in Q3 2025. Positive feedback from the FDA indicates good progress towards this goal. Dr. Leonardo Kayat-Bittencourt has joined as a clinical advisor for the prostate cancer program, bringing valuable expertise. The Company expects completion of the MagSense® HER2 imaging agent manufacture in Q3 2025, pending FDA approval. Expenditures for other cancer programs will be limited based on available funds. Cash flow has decreased, with operating cash outflow reduced mainly due to cost management. The Company is confident in meeting FDA requirements for the IND application and looks forward to a productive second half of 2025. Investors are invited to review the detailed cash flow report in the Appendix 4C for more financial insights. Feel free to reach out with any questions or clarifications regarding this update. Thank you for your continued support and interest in Imagion Biosystems.